This phase II clinical trial evaluated the safety and efficacy of nilotinib in patients with recurrent, platelet-derived growth factor receptor alpha (PDGFRA)-enriched high-grade gliomas. This evidence concerns the gene PDGFRA and central nervous system cancer.